GCIIXICO shares soar on stellar FY24 performance and guidance upgrade
Cracking year-end trading update today from neuro-medical imaging firm () . Here its AI-enhanced analytics help biopharmas and CROs develop new drugs to treat conditions like Huntington's disease, Parkinson's and Alzheimer's.
reported strong performance in H2'24, with sales of £3.0m to £3.4m - or 20% to 36% higher than H1 (£2.5m) levels- thanks to £5.8m of contract wins in the 2nd half and strong cost control.
This means FY24 revenues (£5.5m-£5.9m), LBITDA, net cash and the closing orderbook, should all be better than current market expectations. House broker Cavendish have a 24p/share target price and believe the global clinical trials market is improving.
CEO Giulio Cerroni commenting: "I am pleased with the progress since the half-year, with new contracts signed underpinning revenue growth across H2. In parallel, we have continued to see a strengthening of our opportunities pipeline and whilst we maintain a very close eye on costs, we are doing so in a manner that avoids detriment to our core focus of delivering growth."
shares jumped over 30% on the announcement.
Follow News & Updates from IXICO:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.